Order byBest matchMost fresh
Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.
Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.
One estimate of the profit hit from Trump's executive order on drug pricing
Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels could result in 15% operating profit cuts in the industry.
Merck’s New Keytruda Shot Is a Rare Real-Time ‘Product Hop’ (1)
Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, expand access, and save more lives, the company says. But by shifting patients to a version protected by newer patents,
Pharma stocks recover from initial shock of Trump's drug pricing order
Shares of U.S. drugmakers rebounded on Monday after an initial selloff as analysts said that President Donald Trump's sweeping executive order to slash prescription drug prices would be difficult to implement and face legal challenges.
Pharma Stocks Sink as Trump Announces Plan to Cut Drug Prices
Global pharmaceutical shares are slumping Monday after President Donald Trump said he is looking to slash the price of prescription drugs in the U.S. by as much as 80%.
Trump's plans to assess tariffs on imported drugs could raise prices, cause drug shortages
Patients will likely eventually see higher prices and drug shortages under President Trump's plan to assess tariffs on prescription drug imports.
Reuters7d
Merck & Co Inc
US court shuts down AstraZeneca's challenge to Medicare drug price ... on the impact of U.S. tariffs, tax policy would be a more effective way to influence U.S. manufacturing. Merck to invest ...
FACT FOCUS: Trump Blames Other Countries for High US Drug Prices. Experts Say It's Not Their Fault
President Donald Trump signed an executive order this week setting a 30-day deadline for drugmakers to electively lower prices in the U.S. or face new limits on what the government will pay
Feedback